Un estudio para conocer qué tan bien funciona odronextamab combinado con quimioterapia y qué tan seguro es en comparación con rituximab y quimioterapia en participantes adultos con linfoma folicular no tratado previamente (OLYMPIA-2)
Un estudio de fase 3, abierto y aleatorizado para comparar la eficacia y seguridad de Odronextamab (REGN1979), un anticuerpo biespecífico anti-CD20x anti-CD3, combinado con quimioterapia versus rituximab combinado con quimioterapia en participantes con linfoma folicular no tratados previamente (OLYMPIA- 2)
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participants with follicular lymphoma that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory") are eligible to take part only in Part 1A of the study.
This study is made up of 3 parts: Part 1A (non-randomized), Part 1B and Part 2 (randomized - controlled).
The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy to be used in Part 2 of the study.
The aim of Part 2 of the study is to assess how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab and chemotherapy (the current standard-of-care for NHL). Standard-of-care means the usual medication expected and used when receiving treatment for a condition.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
- The impact from the study drug on quality-of-life and ability to complete routine daily activities
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Kiel, Alemania, 24116
- Stadtisches Krankenhaus Kiel
-
Neuss, Alemania, 41462
- MVZ fuer Haematologie und Onkologie Rhein-Kreis GmbH
-
-
-
-
New South Wales
-
Liverpool, New South Wales, Australia, 2170
- Liverpool Hospital
-
Waratah, New South Wales, Australia, 2298
- Calvary Mater Newcastle
-
-
Queensland
-
Benowa, Queensland, Australia, 4217
- Pindara Private Hospital
-
-
-
-
-
Vienna, Austria, 1090
- Universitatsklinik fur Kinder und Jungendheilkunde
-
Wels, Austria, 4600
- Klinikum Wels-Grieskirchen
-
-
Lower Austria
-
Sankt Pölten, Lower Austria, Austria, 3100
- Karl Landsteiner University Hospital St. Poelten
-
-
Styria
-
Graz, Styria, Austria, 8036
- Medical University of Graz
-
Leoben, Styria, Austria, 8700
- Landeskrankenhaus Hochsteiermark
-
-
Tyrol
-
Innsbruck, Tyrol, Austria, 6020
- Innsbruck Medical University
-
-
Upper Austria
-
Linz, Upper Austria, Austria, 4020
- Kepler University Hospital
-
-
-
-
-
Rio de Janeiro, Brasil, 20231050
- Instituto Nacional de Cancer Jose Alencar Gomes da Silva
-
São Paulo, Brasil, 01323-903
- Hospital Alemao Oswaldo Cruz
-
São Paulo, Brasil, 08270-070
- Casa de Saude Santa Marcelina
-
São Paulo, Brasil, 01509-010
- AC Camargo Cancer Center
-
São Paulo, Brasil, 05403-000
- Clinical Hospital of Medicine School at Sao Paulo University
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasil, 41253-900
- Hospital Sao Rafael
-
Salvador, Estado de Bahia, Brasil, 41950-640
- Ensino e Terapia de Inovacao Clinica Amo (Etica)
-
Salvador, Estado de Bahia, Brasil, 40050-410
- Hospital Santa Izabel - Santa Casa de Misericordia da Bahia
-
-
Federal District
-
Brasília, Federal District, Brasil, 70200-730
- Hospital Sirio Libanes Brasilia
-
Brasília, Federal District, Brasil, 70390-140
- Instituto DOr de Pesquisa e Ensino Df Star
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasil, 30380-472
- Instituto Mario Pena de Ensino Pesquisa e Inovacao
-
Uberlândia, Minas Gerais, Brasil, 38408-008
- Centro Oncologico do Triangulo (COT) - Uberlandia
-
-
Paraná
-
Curitiba, Paraná, Brasil, 81520-060
- Hospital Erasto Gaertner
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brasil, 59062-000
- Liga Norte Riograndense Contra o Cancer
-
-
Rio Grande do Sul
-
Bento Gonçalves, Rio Grande do Sul, Brasil, 95700-084
- Instituto Tacchini de Pesquisa em Saude
-
Passo Fundo, Rio Grande do Sul, Brasil, 99010-080
- Instituto do Cancer em Hospital Sao Vicente de Paulo
-
Porto Alegre, Rio Grande do Sul, Brasil, 90035-903
- Hospital de Clinicas de Porto Alegre
-
-
Santa Catarina
-
Joinville, Santa Catarina, Brasil, 89201-260
- Centro de Hematologia e Oncologia
-
Lages, Santa Catarina, Brasil, 88501-001
- Animi Unidade de Tratamento Oncologico Ltda
-
-
São Paulo
-
Barretos, São Paulo, Brasil, 14784-400
- Fundacao Pio XII Hospital de Amor
-
Jaú, São Paulo, Brasil, 17210-080
- Amaral Carvalho Hospital
-
Ribeirão Preto, São Paulo, Brasil, 14048-900
- Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto
-
-
-
-
-
Brussels, Bélgica, 1000
- Institut Jules Bordet
-
Liège, Bélgica, 4000
- Centre Hospitalier Regional de la Citadelle
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Bélgica, 9000
- Universitair Ziekenhuis (UZ) Gent/ Ghent University Hospital
-
Sint-Niklaas, Oost-Vlaanderen, Bélgica, 9100
- Verenigde Ziekenhuizen van Waas en Durme
-
-
West-Vlaanderen
-
Bruges, West-Vlaanderen, Bélgica, 8000
- Algemeen Ziekenhuis St Jan Brugge Oostende Av
-
Kortrijk, West-Vlaanderen, Bélgica, 8500
- AZ Groeninge
-
-
-
-
North Central Czech Republic
-
Hradec Králové, North Central Czech Republic, Chequia, 50005
- University Hospital Hradec Kralove
-
-
South Moravian
-
Brno, South Moravian, Chequia, 62500
- University Hospital Brno
-
-
-
-
Las Condes
-
Santiago, Las Condes, Chile, 7620157
- Hospital Clinico Universidad de Los Andes
-
-
Santiago Metropolitan
-
Santiago, Santiago Metropolitan, Chile, 7560907
- Centro Oncologia de Precision Universidad Mayor
-
Santiago, Santiago Metropolitan, Chile, 7580206
- Inmunocel
-
Santiago, Santiago Metropolitan, Chile, 7550000
- Pontificia Universidad Catolica de Chile
-
-
-
-
-
Lugo, España, 27003
- Hospital Universitario Lucus Augusti
-
Madrid, España, 28027
- Clinica Universidad de Navarra - Madrid
-
Madrid, España, 28034
- Hospital Universitario Ramon y Cajal
-
Madrid, España, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, España, 28031
- Hospital Universitario Infanta Leonor
-
Madrid, España, 28040
- Hospital Universitario Fundacion Jimenez Diaz
-
Ourense, España, 32005
- Complexo Hospitalario Universitario de Ourense
-
Pamplona, España, 31008
- Clinica Universidad de Navarra- Pamplona
-
Salamanca, España, 37007
- Hospital Universitario de Salamanca
-
Seville, España, 41009
- Hospital Universitario Virgen Macarena
-
Valencia, España, 46009
- Instituto Valenciano de Oncologia
-
Valencia, España, 46010
- Hospital Clinico Universitario de Valencia
-
-
Andalusia
-
Seville, Andalusia, España, 41013
- Hospital Universitario Virgen del Rocio
-
-
Barcelona
-
Sabadell, Barcelona, España, 08208
- Parc Tauli Sabadell Hospital Universitari
-
Terrassa, Barcelona, España, 08221
- Hospital Universitari Mutua Terrassa
-
-
Bizkaia
-
Barakaldo, Bizkaia, España, 48903
- Cruces University Hospital (Hospital Universitario Cruces)
-
-
Madrid
-
Majadahonda, Madrid, España, 28222
- Hospital Universitario Puerta de Hierro - Majadahonda
-
Pozuelo de Alarcón, Madrid, España, 28223
- Hospital Universitario Quiron Salud Madrid
-
-
Navarre
-
Pamplona, Navarre, España, 31008
- Hospital Universitario de Navarra
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, España, 33011
- Hospital Universitario Central de Asturias
-
-
Valencia
-
Alicante, Valencia, España, 03010
- Hospital General Universitario Doctor Balmis Alicante
-
-
-
-
Florida
-
Plantation, Florida, Estados Unidos, 33322
- Boca Raton Clinical Research (BRCR) Global
-
-
Indiana
-
Noblesville, Indiana, Estados Unidos, 46062
- Investigative Clinical Research of Indiana
-
-
Kansas
-
Wichita, Kansas, Estados Unidos, 67214
- Cancer Center of Kansas
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- University of Kentucky
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48202
- Henry Ford Health System
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Cancer and Hematology Centers of Western Michigan
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Center for Oncology and Blood Disorders
-
-
Utah
-
Ogden, Utah, Estados Unidos, 84405
- Community Cancer Trials of Utah
-
-
Wisconsin
-
Waukesha, Wisconsin, Estados Unidos, 53188
- Prohealth Care Inc
-
-
-
-
-
Grenoble, Francia, 38043
- Centre Hospitalier Universitaire de Grenoble
-
Le Puy-en-Velay, Francia, 43012
- Centre Hospitalier Emile Roux
-
Lens, Francia, 62300
- Centre Hospitalier de Lens (Centre Hospitalier Dr Schaffner dLens)
-
Paris, Francia, 75010
- Hopital Saint Louis
-
Pessac, Francia, 33600
- Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Sud - Hôpital Haut Lévêque
-
Saint-Etienne, Francia, 42055
- CHU de Saint-Etienne
-
Saint-Nazaire, Francia, 44600
- Centre Hospitalier de Saint Nazaire
-
-
Alpes Maritimes
-
Cannes, Alpes Maritimes, Francia, 06400
- Cannes Hospital (Centre Hospitalier Cannes Simone Veil)
-
-
Centre-Val de Loire
-
Tours, Centre-Val de Loire, Francia, 37044
- CHRU de Tours
-
-
Gard
-
Nîmes, Gard, Francia, 30029
- Institut de Cancerologie du Gard
-
-
New Aquitaine
-
Mont-de-Marsan, New Aquitaine, Francia, 40024
- Centre Hospitalier de Mont-de-Marsan
-
-
Pays de la Loire Region
-
Nantes, Pays de la Loire Region, Francia, 44093
- Nantes University Hospital
-
-
Pontoise
-
Cergy-Pontoise, Pontoise, Francia, 95300
- The Novo Hospital North West Val Deoise
-
-
Île-de-France Region
-
Argenteuil, Île-de-France Region, Francia, 95100
- Hopital Victor Dupouy Argenteuil
-
-
-
-
-
Beersheba, Israel, 84101
- Soroka University Medical Center
-
Haifa, Israel, 3109601
- Rambam Health Care Campus
-
Jerusalem, Israel, 91200
- Hadassah Medical Center
-
Petah Tikva, Israel, 49100
- Rabin Medical Center
-
Tel Aviv, Israel, 64239
- The Tel Aviv Sourasky Medical Center
-
Tel Aviv, Israel, 6971028
- Assuta Medical Centers
-
-
Jerusalem
-
Jerusalem, Jerusalem, Israel, 9103102
- Shaare Zedek Medical Center
-
-
-
-
-
Milan, Italia, 20141
- Istituto Europeo di Oncologia
-
Milan, Italia, 20162
- ASST Grande Ospedale Metropolitano Niguarda - Main Address
-
Milan, Italia, 20122
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
Modena, Italia, 41124
- A.O.U. di Modena
-
Naples, Italia, 80131
- Federico II University
-
Perugia, Italia, 06132
- Azienda Ospedaliera di Perugia
-
Pisa, Italia, 56126
- University of Pisa, Section of Hematology
-
Potenza, Italia, 85100
- Azienda Ospedaliera Regionale San Carlo
-
Ravenna, Italia, 48121
- UO Ematologia Ravenna
-
Reggio Emilia, Italia, 42123
- Azienda Unita Sanitaria Locale Irccs Arcispedale Santa Maria Nuova
-
Rome, Italia, 00161
- Azienda Osperdaliero-Universitaria Policlinico Umberto 1
-
Udine, Italia, 33100
- Azienda Sanitaria Universitaria del Friuli Centrale
-
-
Forli-Cesena
-
Meldola, Forli-Cesena, Italia, 47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
-
Piedmont
-
Turin, Piedmont, Italia, 10137
- Azienda Ospedaliera Ordine Mauriziano Torino, Presidio Umberto I of Turin
-
-
Sicily
-
Palermo, Sicily, Italia, 90127
- Azienda Ospedaliera Universitario Policlinico Palermo
-
-
-
-
-
Bydgoszcz, Polonia, 85-168
- Szpital Uniwersytecki Nr2 Bydgoszcz
-
Gdansk, Polonia, 80-952
- Uniwersyteckie Centrum Kliniczne, Building of the Non-Invasive Medicine Center
-
Katowice, Polonia, 40-519
- Pratia Onkologia Katowice
-
Lodz, Polonia, 93-513
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Mikolaja Kopernika w Lodzi (Copernicus Memorial Hospital)
-
Lublin, Polonia, 20-954
- Centrum Innowacyjnych Terapii Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie
-
Warsaw, Polonia, 02781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Warszawa
-
Wałbrzych, Polonia, 58-300
- Szpital Szpecjalistyczny w Walbrzychu
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polonia, 30-510
- Matopolskie Centrum Medyczne S.C.
-
-
Wielkopolska
-
Skorzewo, Wielkopolska, Polonia, 60185
- Aidport Sp. z o.o.
-
-
-
-
-
Aberdeen, Reino Unido, AB25 2ZN
- NHS Grampian: Aberdeen Royal Infirmary
-
-
Cornwall
-
Truro, Cornwall, Reino Unido, TR1 3LJ
- Royal Cornwall Hospitals NHS Trust, Royal Cornwall Hospital
-
-
London
-
Uxbridge, London, Reino Unido, UB8 3NN
- The Hillingdon Hospitals NHS Foundation Trust
-
-
West Midlands
-
Birmingham, West Midlands, Reino Unido, B15 2SY
- University Hospitals Birmingham NHS Foundation Trust
-
-
-
-
-
Khon Kaen, Tailandia, 40002
- Khon Kaen University
-
-
Krung Thep Maha Nakhon [Bangko]
-
Bangkok, Krung Thep Maha Nakhon [Bangko], Tailandia, 10330
- Chulalongkorn University
-
-
-
-
-
Kaohsiung City, Taiwán, 83301
- Kaohsiung Chang Gung Memorial Hospital
-
Kaohsiung City, Taiwán, 80756
- Kaohsiung Medical University Hospital
-
New Taipei City, Taiwán, 23561
- Taipei Medical University - Shuang Ho Hospital
-
Taipei, Taiwán, 11217
- Taipei Veterans General Hospital
-
Taipei, Taiwán, 11490
- Tri-Service General Hospital
-
Taipei, Taiwán, 11696
- Taipei Medical University Multipal Wan Fang University
-
-
-
-
-
Ankara, Turquía (Türkiye), 06100
- Liv Hospital Ankara
-
Istanbul, Turquía (Türkiye), 34365
- VKV American Hopital
-
Istanbul, Turquía (Türkiye), 34418
- Istanbul University
-
Kayseri, Turquía (Türkiye), 38039
- Erci̇yes Uni̇versi̇ty
-
Samsun, Turquía (Türkiye), 55270
- Ondokuz Mayıs University
-
Zonguldak, Turquía (Türkiye), 67100
- Zonguldak Bulent Ecevit University
-
-
Ankara
-
Mamak, Ankara, Turquía (Türkiye), 06620
- Ankara University Faculty of Medicine
-
Yenimahalle, Ankara, Turquía (Türkiye), 06200
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
-
Central Anatolia
-
Ankara, Central Anatolia, Turquía (Türkiye), 06100
- Gazi University
-
-
Mersin
-
Mezitli, Mersin, Turquía (Türkiye), 33200
- VM Medical Park Mersin Hospital
-
-
Serdivan
-
Sakarya, Serdivan, Turquía (Türkiye), 54050
- Sakarya University
-
-
Suleymanpasa
-
Tekirdağ, Suleymanpasa, Turquía (Türkiye), 59100
- Tekirdag Namik Kemal University Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Key Inclusion Criteria:
-
Have diagnosis of cluster of differentiation 20 positive (CD20+) FL grade 1-3a, stage II bulky or stage III / IV
- For Part 1A: previously untreated participants who have Follicular Lymphoma International Prognostic Index (FLIPI)-1 score of 3 to 5, or R/R FL
- For Part 1B: previously untreated participants who have FLIPI-1 score of 3 to 5
- For Part 2: previously untreated participants who have FLIPI-1 score of 0 to 5
-
Have measurable disease on cross sectional imaging documented by diagnostic computed tomography [CT], or magnetic resonance imaging [MRI] imaging, as described in the protocol
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
-
Adequate bone marrow and hepatic function.
Key Exclusion Criteria:
- Participants with central nervous system lymphoma or leptomeningeal lymphoma
- Participants with histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma
- Participants with Waldenström macroglobulinemia (WM, lymphoplasmacytic lymphoma), grade 3b follicular lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma
- Recent major surgery and history or organ transplantation
- A malignancy other than NHL unless the participant is adequately and definitively treated and any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol.
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Odronextamab + Chemotherapy
Part 1 of the study includes ordonextamab dose escalation for participants with previously untreated FL and relapsed/refractory FL (Part 1A only) followed by a randomized exploration of 2 regimens of odronextamab (Odro) and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) with the objective of dose optimization (Part 1B) in previously untreated patients with FL. |
Administered by intravenous (IV) infusion
Otros nombres:
Administered by IV infusion
Otros nombres:
Administered by IV infusion
Otros nombres:
Administered orally (PO)
Otros nombres:
|
|
Comparador activo: Rituximab + Chemotherapy
In Part 2 only, participants will be randomized 1:1:1 to receive rituximab (R) with chemotherapy (CHOP), followed by rituximab monotherapy maintenance. |
Administered by intravenous (IV) infusion
Otros nombres:
Administered by IV infusion
Otros nombres:
Administered by IV infusion
Otros nombres:
Administered orally (PO)
Otros nombres:
Administered by IV infusion, or subcutaneous (SC)
Otros nombres:
Administered by IV infusion
Otros nombres:
|
|
Experimental: Odronextamab + Chemotherapy + Maintenance
In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy [CHOP, or cyclophosphamide, vincristine, and prednisone (CVP)], followed by odronextamab monotherapy maintenance. |
Administered by intravenous (IV) infusion
Otros nombres:
Administered by IV infusion
Otros nombres:
|
|
Experimental: Odronextamab + Chemotherapy + No maintenance
In Part 2, participants will be randomized 1:1:1 to receive odronextamab with chemotherapy (CHOP, or CVP) without maintenance. |
Administered by intravenous (IV) infusion
Otros nombres:
Administered by IV infusion
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of dose limiting toxicities (DLTs) for odronextamab in combination with chemotherapy
Periodo de tiempo: Up to 35 days
|
Part 1, DLT period |
Up to 35 days
|
|
Incidence of treatment-emergent adverse events (TEAEs) of odronextamab in combination with chemotherapy
Periodo de tiempo: Up to 2 years
|
Part 1, Treatment period |
Up to 2 years
|
|
Severity of TEAEs of odronextamab in combination with chemotherapy
Periodo de tiempo: Up to 2 years
|
Part 1, Treatment period |
Up to 2 years
|
|
Complete Response rate at 30 months (CR30) assessed by independent central review (ICR)
Periodo de tiempo: Up to 30 months
|
Part 2 |
Up to 30 months
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall Survival (OS)
Periodo de tiempo: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
CR30 as assessed by local investigator
Periodo de tiempo: Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Incidence of TEAEs
Periodo de tiempo: Up to 2 years
|
Part 2 |
Up to 2 years
|
|
Severity of TEAEs
Periodo de tiempo: Up to 2 years
|
Part 2 |
Up to 2 years
|
|
Change in Patient Global Impression of Severity (PGIS)
Periodo de tiempo: Up to 5 years
|
Part 2 The PGIS includes a single-item to assess how a patient perceives the overall severity of cancer symptoms over the past 7 days. Patients will choose the response that best describes the severity of their overall cancer symptoms with options on a 5-point scale ranging from 1 (No symptoms) to 4 (Very Severe). |
Up to 5 years
|
|
Change in Patient Global Impression of Change (PGIC)
Periodo de tiempo: Up to 5 years
|
Part 2 The PGIC item includes a single-item to assess how a patient perceives their overall change in health status since the start of study treatment. Patients will choose from response options on a 7-point scale ranging from 1 (Much Better) to 7 (Much worse); 1- Much Better, 2-Moderately Better, 3-A Little Better, 4-About the Same, 5-A Little Worse, 6-Moderately Worse, 7-Much Worse. |
Up to 5 years
|
|
BOR as assessed by ICR
Periodo de tiempo: Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Odronextamab concentrations in serum when administered with chemotherapy
Periodo de tiempo: Up to 30 months
|
Part 1, Maintenance period and Part 2, Induction period |
Up to 30 months
|
|
Odronextamab concentrations in serum when administered as monotherapy
Periodo de tiempo: Up to 30 months
|
Part 1 and Part 2, Maintenance period |
Up to 30 months
|
|
Incidence of anti-odronextamab antibodies (ADAs)
Periodo de tiempo: Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Titers of ADAs to odronextamab
Periodo de tiempo: Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Incidence of neutralizing antibodies (NAb) to odronextamab
Periodo de tiempo: Up to 30 months
|
Part 1 and Part 2 |
Up to 30 months
|
|
Best overall response (BOR) as assessed by the investigator
Periodo de tiempo: Up to 30 months
|
Part 1, end of Induction period and end of Maintenance period |
Up to 30 months
|
|
Progression free survival (PFS) as assessed by ICR
Periodo de tiempo: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Change in patient reported physical functioning scale scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Cancer-30 (EORTC-QLQ-C30)
Periodo de tiempo: Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a global health status (GHS)/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
PFS as assessed by local investigator
Periodo de tiempo: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Event-free survival (EFS) as assessed by ICR
Periodo de tiempo: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
EFS as assessed by local investigator
Periodo de tiempo: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
BOR as assessed by local investigator
Periodo de tiempo: Up to 30 months
|
Part 2 |
Up to 30 months
|
|
Duration of response (DOR) assessed by ICR
Periodo de tiempo: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
DOR as assessed by local investigator
Periodo de tiempo: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Time to next anti-lymphoma treatment (TTNT)
Periodo de tiempo: Up to 5 years
|
Part 2 |
Up to 5 years
|
|
Change in patient reported health related quality of life (HRQoL) as measured by EORTC-QLQ-C30
Periodo de tiempo: Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Change in cancer disease as measured by EORTC-QLQ-C30
Periodo de tiempo: Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Change in treatment related symptoms as measured by EORTC-QLQ-C30
Periodo de tiempo: Up to 5 years
|
Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden. |
Up to 5 years
|
|
Change in patient-reported lymphoma disease as measured by the Lymphoma Subscale of the Functional Assessment of Cancer Treatment-Lymphoma (FACT-LymS)
Periodo de tiempo: Up to 5 years
|
Part 2 The FACT-Lym lymphoma subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life. |
Up to 5 years
|
|
Change in treatment-related symptoms as measured by the FACT-LymS
Periodo de tiempo: Up to 5 years
|
Part 2 The FACT-LymS includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life. |
Up to 5 years
|
|
Change in patient-reported general health status per EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)
Periodo de tiempo: Up to 5 years
|
Part 2 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state". |
Up to 5 years
|
|
Change in patient-reported treatment side effects burden per Functional Assessment of Cancer Therapy-General Global Population Item 5 (FACT-G GP5)
Periodo de tiempo: Up to 5 years
|
Part 2 A single item GP5 of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4). |
Up to 5 years
|
|
Change in score of the FACT-G GP5 item in the patient population
Periodo de tiempo: Up to 5 years
|
Part 2 A single item GP5 of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4). |
Up to 5 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Clinical Trial Management, Regeneron Pharmaceuticals
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Neoplasias
- Atributos de la enfermedad
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Enfermedades linfáticas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Linfoma No Hodgkin
- Linfoma
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades hemic y linfáticas
- Reaparición
- Linfoma Folicular
- Aminoácidos, péptidos y proteínas
- Proteínas
- Químicos orgánicos
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Hidrocarburos
- Hidrocarburos, cíclico
- Carbohidratos
- Alcaloides
- Hidrocarburos aromáticos policíclicos
- Hidrocarburos, aromáticos
- Compuestos policíclicos
- Glucósidos
- Indoles
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Espierra
- Embarazos
- Esteroides
- Compuestos de anillo fusionado
- Mostaza de fosforamida
- Compuestos de mostaza de nitrógeno
- Compuestos de mostaza
- Hidrocarburos, halogenados
- Fosforamidas
- Compuestos organofosforados
- Esparrazadienetrioles
- Madreadiediols
- Alcaloides de Vinca
- Alcaloides de triptamina de secologanina
- Alcaloides de indol
- Indolizidinas
- Indolizinas
- Antraciclinas
- Naftacenos
- Aminoglucósidos
- Anticuerpos, monoclonales, derivados de murino
- Daunorrubicina
- Prednisolona
- Rituximab
- Prednisona
- Ciclofosfamida
- Doxorrubicina
- Vincristina
- Metilprednisolona
Otros números de identificación del estudio
Otros números de identificación del estudio
- R1979-ONC-2075
- 2022-502113-28-00 (Otro identificador: EUCT Number)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Marco de tiempo para compartir IPD
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Criterios de acceso compartido de IPD
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- CÓDIGO_ANALÍTICO
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .